Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (NCT06779630)
A Prospective Multicenter Single Arm Study to Assess the Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System for the Treatment of Subjects With Atherosclerotic Lesion(s)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm. Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.
Who can join: Review the eligibility criteria below.
Location: John Muir Medical Center — Concord, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- John Muir Medical Center — Concord, California
- Ascension Via Christi Hospitals Wichita — Wichita, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Henry Ford Hospital — Detroit, Michigan
- Barnes Jewish Hospital — St Louis, Missouri
- North Shore University Hospital — Manhasset, New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital — New York, New York
- Baylor Scott & White The Heart Hospital - Dallas — Dallas, Texas
- Ascension Texas Cardiovascular — Kyle, Texas
- Charleston Area Medical Center — Charleston, West Virginia
- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie, Medizinische Universität Wien — Vienna, State of Vienna
- Klinische Abteilung für Kardiologie, Medizinische Universität Graz — Graz, Styria
- Hospices Civils de Lyon - CHU de Lyon — Lyon, Auvergne-Rhône-Alpes
- Clinique Louis Pasteur — Essey-lès-Nancy, Grand Est
- Institut Arnault Tzanck — Saint-Laurent-du-Var, Provence-Alpes-Côte d'Azur Region
- Hôpital Cochin - Groupe AP-HP — Paris, Île-de-France Region
- Universitätsklinikum Mannheim, I. Medizinische Klinik — Mannheim, Baden-Wurttemberg
- Klinikum Fürth — Fürth, Bavaria
- Universitätsklinikum Würzburg — Würzburg, Bavaria
- Segeberger Kliniken GmbH — Bad Segeberg, Schleswig-Holstein
- Miedziowe Centrum Zdrowia SA — Lubin, Lower Silesian Voivodeship
- University hospital Basel — Basel, Canton of Basel-City
- Istituto Cardiocentro Ticino — Lugano, Canton Ticino
📞 Contact the Study Coordinator
Phone: (866) 246-6990
Email: bioflow-48@teleflex.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Coronary Artery Disease
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended — Stanford, California
- Genomic Investigation of Cardiovascular Diseases — La Jolla, California
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health — Boston, Massachusetts
- A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD — Mobile, Alabama
- Firehawk Rapamycin Target Eluting Coronary Stent North American Trial — Birmingham, Alabama
- Precision PCI Registry — Gainesville, Florida
Explore by condition: All Coronary Artery Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.